Determining the optimal treatment course and predicting outcomes may get easier in the future for patients with head and neck sqaumous cell carcinomas with the use of an investigational imaging agent. New research shows that positron emission tomography imaging with 3′-deoxy-3’F-18-fluorothymidine during treatment and early follow-up has the potential to predict therapeutic responses.